Piper Jaffray
Fulgent Genetics Prices $26.2M Public Stock Offering
The genetic testing firm is offering approximately 2.3 million shares at $11.25 per share and plans to use the funds for general corporate purposes.
Pacific Biosciences Stock Upgraded by Piper Jaffray
The bank believes investors are too focused on the potential of PacBio's merger with Illumina falling through rather than recent developments regarding its technology.
Fulgent Genetics to Offer $22.5M in Stock
The genetic testing firm has entered into an equity distribution agreement with Piper Jaffray to offer up to $30 million in stocks, with an initial offering of $22.5 million.
Genomic Health Upgraded to Overweight by Piper Jaffray
The investment bank cited management confidence in US and European test growth as meriting the upgrade, which was necessary to maintain a current $72 price target on the firm's stock.
Piper Jaffray Initiates Coverage of OncoCyte With Overweight Rating
An analyst said the DetermaVu test could potentially be best in class for lung cancer diagnosis and that CMS could begin reimbursing for it in late 2020.